A multi-ancestry genome-wide study incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure by  et al.
                                                                    
University of Dundee
A multi-ancestry genome-wide study incorporating gene-smoking interactions
identifies multiple new loci for pulse pressure and mean arterial pressure
LifeLines Cohort Study; Sung, Yun Ju; de Las Fuentes, Lisa; Winkler, Thomas W.; Chasman,
Daniel I.; Bentley, Amy R.
Published in:
Human Molecular Genetics
DOI:
10.1093/hmg/ddz070
Publication date:
2019
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
LifeLines Cohort Study, Sung, Y. J., de Las Fuentes, L., Winkler, T. W., Chasman, D. I., Bentley, A. R., Kraja, A.
T., Ntalla, I., Warren, H. R., Guo, X., Schwander, K., Manning, A. K., Brown, M. R., Aschard, H., Feitosa, M. F.,
Franceschini, N., Lu, Y., Cheng, C-Y., Sim, X., ... Morrison, A. C. (2019). A multi-ancestry genome-wide study
incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial
pressure. Human Molecular Genetics, 28(15), 2615-2633. https://doi.org/10.1093/hmg/ddz070
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. Jun. 2020
1 
A multi-ancestry genome-wide study incorporating gene-smoking 
interactions identifies multiple new loci for pulse pressure and mean 
arterial pressure 
Date: 08/29/18 
Yun Ju Sung et al 
(The full list of authors and affiliations appears at the end) 
Address Correspondence to: 
Yun Ju Sung 
Washington University School of Medicine 
Division of Biostatistics 
Campus Box 8067 
660 S. Euclid Ave. 
St. Louis, MO  63110-1093 
Phone: (314) 362-0053 
Email: yunju@wustl.edu 
Author Accepted Manuscript: LifeLines Cohort Study 2019, 'A multi-ancestry genome-wide study incorporating gene-
smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure' Human Molecular 
Genetics. https://doi.org/10.1093/hmg/ddz070
2 
 
 
Abstract 
Elevated blood pressure (BP), a leading cause of global morbidity and mortality, is 
influenced by both genetic and lifestyle factors. Cigarette smoking is one such lifestyle factor. 
Across five ancestries, we performed a genome-wide gene-smoking interaction study of mean 
arterial pressure (MAP) and pulse pressure (PP) in 129,913 individuals in stage 1 and follow-up 
analysis in 480,178 additional individuals in stage 2. We report here 139 loci significantly 
associated with MAP and/or PP. Of these, 61 were previously published through main-effect 
analysis of BP traits, 37 were recently reported by us for SBP and/or DBP through gene-smoking 
interaction analysis, and 41 were newly identified (P < 5×10-8, FDR < 0.05). We also identified 
11 new signals near known loci. Eight of the 139 loci showed significant interaction with 
smoking status. They include CSMD1 previously reported for insulin resistance and BP in the 
spontaneously hypertensive rats. Many of the 41 new loci show biologic plausibility for a role in 
BP regulation. SLC26A7 encodes a chloride/bicarbonate-exchanger expressed in the renal outer 
medullary collecting duct. AVPR1A is widely expressed including in vascular smooth muscle 
cells, kidney, myocardium, and brain. FHAD1 is a long non-coding RNA overexpressed in heart 
failure. TMEM51 was associated with contractile function in cardiomyocytes. CASP9 plays a 
central role in cardiomyocyte apoptosis. Identification of several novel loci was only possible 
from African ancestry. Our findings highlight the value of multi-ancestry investigations, 
particularly in studies of interaction with lifestyle factors, where genomic and lifestyle 
differences may contribute to novel findings. 
Words: 249 (250 words max in AJHG)  
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Introduction  
Elevated blood pressure (BP), a leading cause of morbidity and mortality worldwide, is 
known to be influenced by both genetic and lifestyle factors. To date genome-wide association 
studies (GWAS) have identified 578 BP-associated genetic variants residing within about 430 
loci.1-8 The effects of genetic variants on BP may manifest differently depending on lifestyle 
exposures. Therefore, incorporating gene-environment (GxE) interactions may identify 
additional loci.9; 10 We established the Gene-Lifestyle Interactions Working Group within the 
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium in 
order to assess the impact of interactions with multiple lifestyle factors on the genetics of 
cardiovascular traits.11 Among many lifestyle factors, cigarette smoking influences BP in both 
acute12 and chronic13 fashion, motivating genetic association studies of gene-by-smoking 
interactions.  
Recently we reported findings from a genome-wide association meta-analysis 
incorporating gene-smoking interactions for systolic BP (SBP) and diastolic BP (DBP).14 In 
addition to SBP and DBP, blood pressure can also be characterized as having both steady and 
pulsatile components, each determined by different physiologic properties of the heart and 
vasculature, and differently related to cardiovascular outcomes. Mean arterial pressure (MAP) 
reflects the steady component of BP, which is predominantly determined by cardiac output and 
systemic vascular resistance and regulated by small artery and arteriole tone.15 Pulse pressure 
(PP) represents the pulsatile component of BP and is largely determined by cardiac stroke 
volume and large artery stiffness.15; 16 In this study, we performed a genome-wide association 
meta-analysis of MAP and PP incorporating gene-smoking interactions (Figure 1). Here, we 
report our findings based on 610,091 individuals across five ancestries.  
Methods  
Participating Studies 
Analyses included men and women between 18-80 years of age from European (EUR), 
African (AFR), Asian (ASN), Hispanic (HIS), and Brazilian (BRZ) ancestries. Forty-eight (48) 
cohorts consisting of 129,913 individuals (Table S1) participated in stage 1 and performed 
genome-wide analyses. Studies that included data from multiple ancestries (cohorts) contributed 
multiple analyses, one for each ancestry/cohort. For example, MESA has four cohorts. Seventy-
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six (76) additional cohorts consisting of 480,178 individuals (Table S2) participated in stage 2 
and performed association analyses of 4,373 variants that were identified in stage 1 as either 
genome-wide significant (P < 5×10-8) or suggestive (P < 10-6). All participating studies are 
described in the Supplemental Notes. Since discoveries of BP loci to date were largely from 
EUR populations, considerable effort was made for recruiting most of the available non-EUR 
cohorts into stage 1 (which limited the availability of non-EUR cohorts in stage 2). Each study 
obtained informed consent from participants and approval from the appropriate institutional 
review boards.  
Phenotypes and Lifestyle Variables 
Resting systolic BP (SBP) and diastolic BP (DBP) were measured using a consistent 
protocol. For individuals on any anti-hypertensive (BP lowering) medications, 15 mmHg and 10 
mmHg were added to their SBP and DBP values, respectively.1 PP was computed as SBP minus 
DBP (PP = SBP – DBP) and MAP was computed as the sum of DBP and one-third of PP (MAP 
= DBP + PP/3). To reduce the influence of possible outliers, each BP value was winsorized at 6 
standard deviations away from the mean (i.e., values greater than 6 SD away from the mean were 
set at 6 SD). 
We considered two of the most widely available smoking variables: ‘current smoking’ 
status (CurSmk) and ‘ever smoking’ status (EverSmk) (Table 1). Current smoking status was 
defined as 1 if the individual smoked regularly in past year (and as 0 for non-current smokers, 
which includes both never and former smokers). Ever smoking status was defined as 1 if the 
individual smoked at least 100 cigarettes during his/her lifetime (and as 0 for the never-smokers). 
Smoking status was assessed at the time of the BP measurements. Covariates include age, sex, 
field center (for multi-center studies), and principal component (PC)s (to account for population 
stratification and admixture). No additional covariates were included. Individuals with missing 
data for BP, the smoking variable, or any covariates were excluded from analysis. Study-specific 
summary statistics on phenotypes are presented in Tables S3-S4.  
Genotype Data 
Genotyping was obtained using Illumina (San Diego, CA, USA) or Affymetrix (Santa 
Clara, CA, USA) genotyping arrays. Each study performed genotype imputation at single 
nucleotide polymorphisms (SNPs), short insertions and deletions (indels), and larger deletions 
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that were not genotyped directly but are available from the 1000 Genomes Project.17 For 
imputation, most studies used the 1000 Genomes Project Phase I Integrated Release Version 3 
Haplotypes (2010-11 data freeze, 2012-03-14 haplotypes), which contain haplotypes of 1,092 
individuals of all ancestry backgrounds. Study-specific information on genotyping and 
imputation is presented in Tables S5-S6.  
Cohort-specific Analysis 
Participating studies performed association analyses separately within each ancestry for 
MAP and PP incorporating current smoking (CurSmk) and ever smoking (EverSmk). All studies 
performed regression analysis using a model with both genetic main and GxE interaction 
effects18 and provided the estimated genetic main and interaction effects and a robust estimate of 
the corresponding covariance matrix. In addition, studies in stage 1 performed regression 
analyses with the genetic main-effect model, in the exposed (Smk=1) and unexposed strata 
(Smk=0) separately, and provided estimates of the stratum-specific effects and robust estimates 
of their standard errors (SE). Either sandwich19 or ProbABEL20 packages were used to obtain 
robust estimates of covariance matrices and robust SEs for samples of unrelated individuals. 
Family studies used the generalized estimating equations (GEE) approach, treating each family 
as a cluster, or the linear mixed effect model approach with a random polygenic component (for 
which the covariance matrix depends on the kinship matrix). Robust estimates of covariance 
matrices and SEs were used to safeguard against mis-specification of the mean model and 
violation of the assumption of constant BP variance across smoking groups 
(heteroscedasticity).21; 22  
Quality Control (QC) 
We performed extensive QC using the R package EasyQC23 for all cohort-specific 
results. For GWAS results in stage 1, each cohort applied a preliminary filter on their imputed 
data excluding variants with minor allele frequency (MAF) < 1%. Variants with imputation 
quality measure < 0.5 were subsequently excluded. We performed the “study-level” QC, which 
included carefully checking the observed allele frequencies against the corresponding ancestry-
specific 1000 Genomes Project data and harmonizing marker names to ensure consistencies 
across cohorts. In addition, in stage 1, we compared results from the joint and stratified models, 
as explained elsewhere.24 To identify cross-study issues, we then performed the “meta-level” QC 
by checking result files across all cohorts for each analysis. This included visually comparing 
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summary statistics (mean, median, inter-quartile range, etc.) on all effect estimates, SEs and p-
values, and examining SE-N and QQ plots to reveal issues with trait transformation23 or other 
analytical problems. Encountered QC problems were communicated and resolved with the 
individual cohorts. More detailed information about QC is described elsewhere.11; 14 
Meta-analyses 
After selecting high-quality variants through extensive QC, approximately 18.8 million 
SNPs and small insertion and deletion (indels) variants were included in the meta-analysis (the 
number of variants varied across the ancestry groups). To combine cohort-specific results within 
each ancestry, we first performed ancestry-specific meta-analyses; the results were then 
combined through meta-analysis to obtain evidence of “trans-ancestry” association. Inverse-
variance weighted meta-analysis with METAL25 was used for the 1 degree of freedom (DF) test 
of interaction effect (with H0: βGE = 0). For 2 DF tests of both SNP main and interaction effects 
(with H0: βG = βGE = 0), the joint meta-analysis of Manning et al26 was used. In the stratified 
model, we performed meta-analysis using the approach of Randall et al27 for the 1 DF test and 
the approach of Aschard et al28 for the 2 DF test using the R package EasyStrata.29 Additional 
details about the meta-analytic approach are described elsewhere.24  
In stage 1, genomic control correction30 was applied twice, first for cohort-specific 
GWAS results if their genomic control lambda value was greater than 1, and again after the 
meta-analysis. Variants that passed QC were excluded if they were represented in fewer than 
5,000 samples from at least 3 cohorts. Variants that were genome-wide significant (P < 5×10-8) 
or suggestive (P < 1×10-6) in stage 1 were pursued in stage 2. Heterogeneity p-values at the 
selected variants were > 1×10-5, indicating limited heterogeneity (data not shown). In stage 2, 
genomic control correction was not applied to the replication statistics as association analysis 
was performed only at select variants. Meta-analysis combining results of stages 1 and 2 was 
also performed. In addition, genome-wide significant variants in stage 1 were tested for formal 
replication in stage 2 using Bonferroni-corrected significance threshold.   
Genome-wide Significant Variants 
We considered a variant with P < 5×10-8 to be genome-wide significant. False discovery 
rate (FDR) q-values were computed using the R function p.adjust using the step-up method by 
Benjamini and Hochberg.31 To identify a set of independent (index) variants, we performed the 
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linkage disequilibrium (LD)-based clumping procedure using PLINK32 and EasyStrata.29 A locus 
is defined through LD-based clumping that uses physical distance (± 1 Mb) and LD threshold of 
r2 > 0.1. Since valid methods do not exist for conditional analysis involving interactions across 
multi-ancestry studies, we relied on a relatively more stringent LD threshold (r2 > 0.1) for 
identifying “independent” loci. For LD reference, ancestry-specific 1000 Genomes Project data 
were used for ancestry-specific results and the entire cosmopolitan dataset was used for trans-
ancestry results. 
BP Variance Explained  
We computed BP variance explained by genome-wide results, based on stage 1 stratified 
results with current-smoking status in European ancestry.33 Within each of the smoking strata, 
we computed the variance of MAP and PP explained by subsets of variants selected using 15 
significance thresholds ranging from 1×10-8 to 0.1 
Functional Inferences 
We conducted DEPICT analyses34 based on genome-wide significant (P < 5×10-8) 
variants from the combined analysis of stages 1 and 2. DEPICT performs three consecutive 
analyses: i) gene prioritization at the identified loci; ii) gene set enrichment analyses; and iii) 
tissue- and cell-type specific expression analyses. To obtain input for the analyses, DEPICT 
applied a combined distance and LD based threshold (500 kb flanking regions and LD r² > 0.1) 
between the identified variants and the 1000 Genomes reference data35. A further clumping (LD 
r2 > 0.5 between the non-overlapping variants and known functional coding or cis-acting 
regulatory variants) was used to obtain a list of genes overlapping with the identified variants. 
The major histocompatibility complex region on chromosome 6 (25 Mb – 35 Mb) was removed 
for further analyses.  
For gene prioritization, DEPICT compared functional similarity of genes across 
identified loci using a gene score, which was adjusted for confounders like gene length. To 
obtain FDR, the scoring was repeated 50 times based on 500 pre-compiled null GWAS. For 
gene-set enrichment analyses, DEPICT used 14,461 pre-compiled reconstituted gene sets; they 
include 737 Reactome pathways, 2,473 phenotypic gene sets (derived from the Mouse Genetics 
Initiative), 184 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, 5,083 Gene 
Ontology terms, and 5,984 protein molecular pathways (derived from protein-protein 
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interactions). For tissue and cell type enrichment analyses, DEPICT used expression data from 
the 209 MeSH annotations for 37,427 microarrays of the Affymetrix U133 Plus 2.0 Array 
platform.  
Results 
Overview 
Through genome-wide search of meta-analyses with 129,913 individuals in stage 1, we 
identified 1,692 significant (P ≤ 5×10-8) and 2,681 suggestive (P ≤ 10-6) variants associated with 
MAP and/or PP. We performed meta-analysis combining stages 1 and 2 (Manhattan plots Figure 
S1; Quantile-quantile, QQ, plots Figure S2). Through this combined analysis with 610,091 
individuals, we identified 41 novel genome-wide significanct loci (P ≤ 5×10-8) that are at least 
1Mb away from any of known BP loci (Table 2). We also identified 11 additional new signals 
near (but not in LD, r2 < 0.1, with) known BP loci (Table 3). LocusZoom plots are shown in 
Figure S3. FDR q-values provided additional evidence for these newly-identified loci (FDR < 
0.01 for 48 of the 52; and FDR < 0.05 for all 52 loci).  
Among the 81 loci we reported recently through gene-smoking interactions for SBP 
and/or DBP14, thirty-seven (37) were also associated with MAP and/or PP (Figure 2, Table S7). 
Among the previously published loci through main effects GWAS for any BP trait,1-8 sixty-one 
(61) loci showed association with MAP and PP as well. Among the genome-wide significant 
variants in stage 1, which resided in 112 independent loci, 53 loci were formally replicated in 
stage 2 using Bonferroni-adjusted significance levels (P < 0.05/112). All of them had been 
identified previously; 44 through main effects GWAS,1-8 and 9 through gene-smoking interaction 
analysis we reported recently for SBP and DBP.14  
The Role of Interactions 
In total, we identified 139 loci and 11 new signals significantly-associated with MAP 
and/or PP: 41 new loci, 11 new signals near known BP loci, 37 recently reported by us for SBP 
and/or DBP,14 and 61 previously published through main-effect GWAS analysis of BP traits.1-8 
Among them, variants at eight loci showed genome-wide significant interactions (1 DF 
interaction P < 5×10-8) with smoking status (Figure 3). All 8 loci were identified with current 
smoking status; these variants have larger effects in current smokers than in non-current 
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smokers. Five interactions were newly identified (Table 2), and the other 3 were previously 
reported for SBP or DBP (Table S7). These variants showing interaction effects were identified 
only in individuals of African ancestry in stage 1. Because of the limited sample size of African 
ancestry in stage 2, no replication of their interactions was attempted in stage 2.  
BP Variance Explained  
Within each of the smoking strata, we computed the variance of MAP and PP explained 
by genome-wide results33 in European ancestry (Figure 4). The independent set of variants, 38 
for MAP and 12 for PP, with P ≤ 5×10-8 explained 1.9% of variance in MAP and 0.5% of 
variance in PP. The difference in explained variance between the smokers and non-smokers was 
not significant, suggesting that BP variance explained by interaction effects is very small. 
Similar inference was observed with the results from ever-smoking status (data not shown).  
Functional Inferences 
To obtain functional annotations from HaploReg,36 we focused on the index variants 
representing the 89 loci (41 novel loci, 11 new signals near known loci, and 37 recently reported) 
that showed association with MAP and/or PP. There was one missense variant, rs1009382. Of 
the remaining non-coding variants (37 intronic and 51 intergenic), 15 were in promoter histone 
marks, 47 in enhancer histone marks, 28 in DNase I marks, and 8 altered the binding sites of 
regulatory proteins (Table S8). Using GERP37, 5 variants were identified as being conserved 
among vertebrates, with 3 variants identified as such using SiPhy.38 For 27 variants, cis-eQTL 
evidence was available with varying degrees of association with expression probes. In particular, 
10 of them were identified by GTEx39 as cis-eQTLs across various tissues (Table S9). In 
addition, we obtained information on microarray-based gene and exon expression levels in whole 
blood from over 5,000 individuals of the Framingham Heart Study40 (Table S10). There were 
109 variant-transcript pairs (representing 26 variants) with cis-eQTL evidence (at P < 8.9×10-5, 
FDR < 0.002). Among 26 variants, the 3 variants had the most significant eQTL evidence: 
rs112947839, rs1009382, and rs7753826 associated with 21, 18, and 10 transcripts, respectively. 
The DEPICT analyses prioritized genes (FDR < 5%) at 40 loci, including 16 genes that 
did not match the nearest gene of the identified lead variant (Table S11). Furthermore, the 
analyses highlighted 56 significantly (FDR < 5%) enriched gene sets. Many of these highlight 
cardiovascular mechanisms, such as ‘abnormal blood vessel morphology’, ‘thin myocardium’ or 
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‘abnormal heart development’, Table S12). We also observed that genome-wide significant 
MAP and PP loci are enriched for genes expressed in the ileum (Table S13).  
Associations of BP Loci with Cardiometabolic Traits  
We obtained association results of the 89 index variants associated with MAP or PP 
(representing 41 novel loci, 11 new signals near known loci, and 37 recently reported loci) with 
multiple cardiometabolic traits: coronary artery disease (CAD), stroke, adiposity, diabetes, and 
renal function (Tables S14-S19). For 36 out of 47 scenarios (highlighted in red, Table S20), the 
observed number of variants with nominal evidence of association (P < 0.05) was higher than 
that expected by chance alone (PBinomial < 0.05/11, corrected for 11 traits used in the lookups). 
For example, we observed 7 and 11 such associations with CAD and myocardial infarction, 
respectively, where the expected count is 2.2 for both traits. Corroborating evidence of the 
multiple cardiometabolic traits were found for the eight of the 52 new loci: rs2071405, AGT; 
rs146622638, GPM6A; rs1009382, TNXB; rs6601302, LOC157273; rs7005363, MSRA; 
rs12156238, FAM167A; rs1010064, LOC100506393; rs201028933, LOC338758. These 
overlapping signals support that these traits may share a common pathophysiology. 
Loci Overlapping with Previously Reported SBP or DBP Loci 
Among the loci that were reported by us recently as significantly associated with SBP 
and/or DBP based on gene-by-smoking interaction analysis,14 thirty-seven (37) were also 
associated with MAP and/or PP (Table S7). Among them, 9 loci were formally replicated in 
stage 2 and showed association with all 4 BP traits. Variants at these nine loci were all also 
genome-wide significant in the combined analysis of stages 1 and 2 in individuals of European 
ancestry. For variants at six of the nine loci, there was supporting evidence of association in 
individuals of non-European ancestry, which resulted in stronger statistical significance from 
trans-ancestry analysis. One such locus was rs351364 (in WNT2B), where only trans-ancestry 
analysis reached genome-wide significance in stage 1; the direction of the genetic effect was 
consistent across all ancestries.  
New Signals near Known BP Loci 
Eleven (11) new signals were identified near known BP loci (but not in LD, r2 < 0.1). 
One such signal was rs140881076 (chr1:15364113, Figure 5A) in association with PP in 
individuals of African ancestry. This signal is 434 kb away and in complete linkage equilibrium 
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with CELA2A locus (rs3820068, chr1:15798197) which was recently identified in individuals of 
European ancestry.7; 8 Several nearby genes have been implicated in cardiovascular traits. 
FHAD1 is a long non-coding RNA overexpressed in heart failure,41 TMEM51 has been 
associated with contractile function in cardiomyocytes,42 and CASP9 plays a central role in 
cardiomyocyte apoptosis.43 A candidate gene study identified a missense mutation in CASP9 as 
associated with ischemic stroke in Koreans,44 Differential methylation patterns in TMEM51 have 
also been described in peripheral blood leukocytes of smokers.45; 46   
Through trans-ancestry analysis, we identified one locus (rs1010064) associated with 
both MAP and PP. This is ~500 kb upstream of but not in LD with PDE3A, a known BP gene 
with a role in regulating growth in vascular smooth muscle cells.4; 47 Missense mutations in 
PDE3A have been linked with autosomal dominant syndrome characterized by treatment-
resistant hypertension and brachydactyly.48; 49 SNPs in this locus have also shown suggestive 
associations with aortic root diameter,50 resistant hypertension,51 and SBP in a SNP-alcohol 
consumption interaction analysis.52  
New BP Loci 
Several genes near the 41 novel loci show biologic plausibility for a role in BP 
regulation. One such gene is CSMD1 (rs140994551, chr8:4449086, associated with PP in 
individuals of African ancestry while considering interaction with current smoking status, Figure 
5B). In animal models, variants in CSMD1 were associated with both insulin resistance and BP 
in the spontaneously hypertensive rats.53 In humans, there was suggestive evidence of association 
with hypertension in two Korean cohorts,54 with peripheral artery disease in a Japanese 
population,55 with waist-hip ratio adjusted for BMI in men,56 with insulin resistance in African 
Americans,57 and with studies of addiction and related disorders.58 Another new locus is LRRC69 
(rs11991823, chr8:92188440, associated with PP, identified through trans-ancestry analysis, 
Figure 5C). A copy number variant in this gene has been shown to be weakly associated (P = 
0.04) with BP in a Korean population.59 The nearby gene SLC26A7 encodes a 
chloride/bicarbonate-exchanger expressed specifically in the renal outer medullary collecting 
duct.60 Two PP loci include genes involved in the NFkB signaling pathway (TNFRSF11A and 
NFIB). This inflammatory pathway has been implicated in hypertension-induced renal 
dysfunction in murine models,61 and with endothelial dysfunction in overweight/obese and older 
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humans.62 There was suggested evidence of association of variants in TNFRSF11A with BP traits 
in Chinese women.63  
A new locus near AVPR1A (rs146924684 chr12:63437286, associated with MAP, Figure 
5D) also has strong biologic plausibility. Vasopressin is an antidiuretic hormone and a potent 
vasoconstrictor that exerts its effect through activation of a family of receptors, including the 
arginine vasopressin receptor subtype 1A (AVPR1A) which is widely expressed including in 
vascular smooth muscle cells, kidney, myocardium, and brain.64 In glomerular macula densa 
cells, AVPR1A facilitates activation of the renin-angiotensin-aldosterone system and increases 
expression of the aquaporin 2 water channel.65 AVPR1A stimulation is also necessary for 
maintaining normal BP; in murine knockout models, basal BP is significantly decreased and the 
arterial baroreceptor reflex markedly impaired.66 Notably, there is data to support a role for 
vasopressin not only in the maintenance, but also in the development, of hypertension. 
Vasopressin receptor 1A blockade in young, still normotensive, spontaneously hypertensive rats 
(SHR) attenuates the later development of hypertension in adult SHR despite withdrawal of drug 
therapy.67  
New Loci Related to the Reported BP Regulation   
 We identified several loci with potential relevance to the structure and function of primary cilia, 
in addition to those we reported recently.14 Three PP-associated loci were near genes implicated 
with nephronophthisis, including those with mutations linked to Bardet-Biedl Syndrome (BBS7 
and MYO3A) and with Joubert Syndrome (AHI1). Another PP-associated locus was near 
NEDD4L, which encodes the E3 ubiquitin ligase NEDD4-2 and has been shown to regulate a 
renal epithelial sodium channel (ENaC/SCNN1) that is critical for maintenance of sodium 
homeostasis.68 ENaC is the channel responsible for the monogenetic disorder of BP regulation, 
Liddle Syndrome. Loss of NEDD4-2 in the renal tubules results in increased activity of the 
ENaC channel, resulting in salt-sensitive hypertension.69 Candidate gene studies identified 
variants in NEDD4L as associated with sodium lithium countertransport,70 hypertension,71 
treatment response to β-blockers, and diuretics in hypertensive patients.71-73 
We identified two additional loci with potential relevance to the dopaminergic system, in 
addition to those we reported recently.14 Dopamine signaling plays a key role in both central and 
peripheral BP regulation.74-76 A regulatory subunit (PPP2R2A) of the dopamine receptor 2R 
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(D2R) was associated with MAP. In murine renal proximal tubule cells, inhibition of this 
regulatory protein leads to increased expression of markers of renal inflammation and injury.77 A 
newly identified MAP-associated locus SESN2 is also related to the dopaminergic system; 
activation of the D2R has been shown to increase the expression of SESN2, which protects the 
kidney against renal oxidative stress.78 SESN2 also protects endothelial cell lines against 
angiotensin II-induced endothelial toxicity.79 Two additional loci include genes involved in 
dopamine signaling (ATP13A280 and ARPP2181). Activation of dopamine centers of the brain has 
also been implicated in drug and nicotine abuse.82 
In addition, we found a PP-associated locus near SDHB, which encodes the mitochondrial 
protein succinate dehydrogenase. Variants in this gene have been identified in individuals with 
carotid body tumors and pheochromocytomas/paragangliomas, endocrine tumors that secrete 
dopamine and/or norepinephrine and can modulate BP regulation even when tumors are not 
clinically apparent.83; 84 Variants near this locus have been marginally associated with DBP in 
pre-pubertal European children.85 Tyrosinase (with its related protein, TYRP1) catalyzes the first 
rate-limiting step in pathway in the formation of L-Dopa.86 Although variants in TYRP1 were 
suggestively associated with SBP by the International Consortium for Blood Pressure,87 we 
identified this locus as associated with PP at genome-wide significance.  
Discussion 
Mean arterial pressure (MAP) measures the steady component, which is a function of the 
left ventricular contractility, heart rate, small-artery resistance and vascular elasticity averaged 
over time.15 Pulse pressure (PP) measures the pulsatile component, which is a function of the left 
ventricular stroke volume, large-artery stiffness, early pulse wave reflection, and heart rate.88 
These BP traits not only differ in their physiologic properties, but are also differently related to 
cardiovascular outcomes.15; 88-90 Our genome-wide association meta-analysis incorporating gene-
smoking interactions identified 139 loci significantly-associated with MAP and/or PP: 61 were 
previously published through main-effect GWAS analysis,1-8 37 were recently reported by us for 
SBP and/or DBP through gene-smoking interaction analysis,14 41 are newly reported here. Our 
analysis also identified 11 new signals near known BP loci (but not in LD, r2 < 0.1).  
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Among the loci significantly associated with MAP and/or PP, 8 loci showed significant 
interaction with smoking status from the 1 DF interaction tests. At these 8 loci, the joint 2 DF P-
values ranged from 1×10-7 to 5×10-11, indicating that loci were identified mostly because of their 
interaction with smoking status. One such locus is CSMD1. While variants of this gene were 
previously suggested for addiction and related disorders,58 we identified this locus at genome-
wide significance (1 DF P = 4.3×10-9, 2 DF P = 2.1×10-11). In our study, another locus near AHR 
showed weak evidence of interaction with smoking (1 DF P = 1.6×10-4, 2 DF P = 1.7×10-9 
associated with MAP). Variants in AHR are shown to interact with variants in CYP1A1, a 
detoxifying enzyme, to explain BP differences between smokers and non-smokers.91 AHR 
encodes a ligand-activated transcription factor, and AHR knock-out mice have increased MAP 
and ventricular hypertrophy/fibrosis with increased plasma levels of angiotensin II.92 Given the 
evidence that environmental toxins, including tobacco smoke, activate AHR, it is pertinent to 
note that AHR, in turn, activates tyrosinase activity, the rate limiting step for L-dopa 
biosynthesis.86 Activation of the AHR protein represses T-cadherin expression, which functions 
as a negative growth regulator in vascular smooth muscle cells.93; 94 T-cadherin (encoded by 
CDH13) has been previously identified as a BP susceptibility locus.95 Notably, while the 
endogenous ligand for AHR remains uncertain,96 exogenous ligands include polycyclic aromatic 
hydrocarbons which are found in tobacco smoke and other environmental pollutants.97  
We found that most of MAP-associated loci were previously associated with SBP and/or 
DBP. This is not surprising given that MAP is closely related physiologically to SBP and DBP. 
In contrast, analysis of PP yielded a greater number of novel significant loci that are unique to 
PP. Loci associated with PP may be identifying different physiologic processes than loci 
associated with MAP, SBP and DBP. For example, the steady component of BP can be 
effectively targeted by β-adrenergic receptor and calcium-channel blockers that both modulate 
arteriolar tone. Angiotensin converting enzyme (ACE) inhibitors, which favor remodeling of 
vascular connective tissue, may impact PP to a greater extent.98 This is a clinically important 
concept since hypertension is often more effectively treated by combination drug therapy to 
target different physiologic pathways.99  
This large-scale multi-ancestry study has some limitations. First, because most of the 
known BP loci were identified in European and Asian ancestries, considerable effort was made 
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to recruit most of the available studies from the other ancestries into stage 1. Although we were 
able to identify several new loci in African ancestry, the relatively smaller stage 2 sample size of 
African ancestry (n=7,786?) has limited our ability to replicate these new loci. Second, some of 
our new loci identified through the 2DF joint test may have been identified due to a main effect 
because of a larger sample size and more diverse ancestries, not necessarily from gene-smoking 
interaction. Unfortunately, we are unable to verify this because analysis of main effects alone, 
without regard to smoking status, was not performed. Third, conditional analysis (such as 
GCTA) based on summary statistics was not performed because valid methods do not currently 
exist for GxE interactions. In order to infer independence of the loci, we pursued clumping as 
defined by PLINK32 and used stringent thresholds (± 1 Mb and weak LD with r2 < 0.1). Fourth, if 
there is a gene-environment correlation, a potential confounding of GxE with interaction 
between covariate and smoking exposure may exist. This can inflate Type I error of the GxE 
interaction test.100  
In summary, this study identified 41 new loci and 11 new signals near known BP loci that 
are uniquely associated with MAP and/or PP, demonstrating the promise of gene-lifestyle 
interactions for genetic and environmental dissection of BP traits. Variants in several loci were 
identified in individuals of African ancestry, highlighting the importance of genetic studies in 
diverse populations. These African-specific loci were not replicated in stage 2 because of limited 
sample size and, therefore, require further validation. Many of these new loci (including CSMD1, 
TMEM51, SLC26A7, TNFRSF11A, and AVPR1A) show biologic plausibility for a role in BP 
regulation. They include additional loci of potential relevance to the structure and function of 
primary cilia and the dopaminergic system. Eight out of 133 significant loci showed significant 
interaction with smoking status. Because some interactions may be driven by other lifestyle 
factors that are correlated with smoking, a follow-up study such as Tyrrell and her colleague101 
that jointly examines multiple lifestyle factors can shed light on further understanding of the 
nature of the smoking interaction effects on BP. Our findings highlight the value of multi-
ancestry investigations, particularly in studies of interaction with lifestyle factors, where 
genomic and lifestyle differences may contribute to novel findings. 
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Figure legends 
 
Figure 1: Study design 
Summary of data included in this study.  
Smk: smoking status (considering either current smoking or ever smoking status separately); PC: 
principal component; EUR: European; AFR: African; ASN: Asian; HIS: Hispanic; BRZ: 
Brazilian; TRANS; trans-ancestry (i.e., combining all ancestry groups through meta-analysis) 
 
Figure 2: Venn diagram of loci/signals associated with the 4 BP traits 
The diagram shows 133 loci and/or signals that were identified through gene-smoking 
interactions. We had reported 81 loci associated with SBP/DBP,14 among which 37 showed 
association with MAP or PP. In this paper, we newly identified 41 loci (Table 2) and 11 signals 
near known BP loci (Table 3) that are unique to MAP and/or PP.  
SBP: systolic blood pressure; DBP, diastolic blood pressure; MAP: mean arterial pressure; PP: 
pulse pressure 
Figure 3: Smoking-specific genetic effect sizes for MAP or PP  
Among the 139 loci significantly associated with MAP and/or PP, 8 loci show significant 
interactions with smoking exposure status in African ancestry (1 DF interaction P < 5×10-8). 
Smoking-specific effect estimates and 95% confidence intervals for variants associated with BP 
traits are shown as red and blue squares for current-smokers and non-current smokers, 
respectively.  
MAP: mean arterial pressure; PP: pulse pressure; CS: current-smoking 
 
Figure 4: Smoking-specific estimates of variance explained in European ancestry 
The variants with P ≤ 5×10-8 explained 1.9% of variance in MAP and 0.5% of variance in PP, 
whereas variants with P ≤ 10-4 explained 16% of variance in MAP and 11% of variance in PP. 
The vertical line corresponds to FDR = 0.1. 
 
Figure 5: LocusZoom plots for 4 selected loci associated with MAP and/or PP  
(A) rs140881076 (chr1:15364113) was identified in an analysis of individuals of African 
ancestry and is intronic to KAZN; neighboring genes have been implicated in cardiovascular 
traits. FHAD1 is a long non-coding RNA overexpressed in heart failure, TMEM51 has been 
associated with contractile function in cardiomyocytes, and CASP9 plays a central role in 
cardiomyocyte apoptosis. 
 (B) rs140994551 (chr8:4449086), intronic to CSMD1, shows interaction with current smoking in 
individuals of African Ancestry. CSMD1 are shown to be associated with insulin resistance and 
BP in the spontaneously hypertensive rats. CSMD1 is also suggestively-associated with studies 
of addiction and related disorders.   
(C) rs11991823 (chr8:92188440) was associated with PP in trans-ancestry analyses and in 
intronic to LRRC69. The nearby gene SLC26A7 encodes a chloride/bicarbonate-exchanger 
expressed specifically in the renal outer medullary collecting duct. 
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(D) rs146924684 (chr12:63437286) was association with MAP in individuals of African 
ancestry. The nearby gene AVPR1A is widely expressed including in vascular smooth muscle 
cells, kidney, myocardium, and brain.  
CurSmk: current smoking status; EverSmk: ever smoking status; MAP: mean arterial pressure; 
PP: pulse pressure 
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Tables 
 
Table 1: Basic characteristics of cohorts in Stages 1 and 2 in each ancestry. 
  Current Smoker Former Smoker Never Smoker Male  HTN  HT Meds  
Age MAP PP 
 
N % N % N % % % % Mean SD Mean SD Mean SD 
Stage 1 
EUR 14,607 18.1 28,409 35.3 37,535 46.6 32.6 38.2 25.4 54.63 8 94.63 12.9 52.02 13.3 
AFR 5,545 21.5 7,185 27.8 13,121 50.8 26.5 55.9 39.5 54.49 9.1 99.96 14.9 54.67 16.4 
ASN 2,465 18.3 1,677 12.5 9,296 69.2 51.2 46.9 27 55.42 9.7 98.70 13.4 57.86 15.8 
HIS 1,068 12.1 2,160 24.5 5,577 63.3 24.9 43.5 13.3 55.5 11 94.80 13.9 53.55 16.4 
Stage 1 Total 23,685 18.4 39,431 30.7 65,529 50.9 32.8 43.1 27.7 54.74 8.6 96.17 13.4 53.28 14.4 
Stage 2 
EUR 48,198 17 89,597 31.6 145,914 51.4 47.8 44.8 25 55.91 8.6 102.17 13.5 55.29 13.9 
AFR 1,971 29.8 1,579 23.8 3,075 46.4 40.9 54.3 42.8 53.66 10.2 101.21 14.7 53.68 14.8 
ASN 29,485 19.8 40,850 27.4 78,597 52.8 54.9 50.3 33.1 60.76 12.3 98.31 13.9 54.91 14.0 
HIS 2,739 20.3 2,559 18.9 8,231 60.8 41 26.9 16.3 45.86 13.8 91.36 13.7 48.99 13.3 
BRZ 998 22.6 514 11.6 2,902 65.8 48 15.5 6.3 27.78 3.2 89.75 12.3 45.23 9.8 
Stage 2 Total 83,391 18.2 135,099 29.6 238,719 52.2 49.7 45.9 27.4 56.84 9.9 100.54 13.7 54.88 13.9 
TOTAL 107,076 18.3 174,530 29.8 304,248 51.9 46.1 45.3 27.4 56.4 9.6 99.61 13.6 54.54 14.0 
The cell entries for the covariates and BP traits correspond to sample-size weighted averages across all cohorts in each category. EUR: 
European; AFR: African; ASN: Asian; HIS: Hispanic; BRZ: Brazilian; ALL: trans-ancestry (i.e., combining all ancestry groups 
through meta-analysis); HTN: hypertension; MAP: mean arterial pressure; PP: pulse pressure 
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Table 2: Forty-one new loci associated with MAP and/or PP that are at least 1Mb away from any known BP locus 
Locus rsID Nearest Gene Pos Freq1 Race 
Trait/ 
Exposure Effect StdErr 
GxE 
Effect 
GxE 
StdErr 
Interaction  
P Joint P 
FDR q 
value 
1 rs115356163 PADI2 1:17466024 0.02 AFR PP/CS 0.22 0.87 -7.70 1.53 0.04 5.17E-09 3.63E-05 
2 rs147515295 EYA3; SESN2 1:28389841 0.98 HIS MAP/ES 2.94 1.04 2.80 1.52 0.10 3.47E-08 0.018721 
3 rs11587661 COG2 1:230671208 0.02 AFR PP/CS 0.44 0.86 -7.63 1.51 1.31E-06 4.95E-08 0.010168 
4 rs138318054 KIAA1804 1:233578559 0.02 AFR PP/CS -0.37 0.93 -7.58 1.66 1.40E-05 4.84E-08 0.010095 
5 rs79113694 GALNT14 2:31253799 0.03 AFR PP/ES -0.60 0.58 -2.91 0.83 1.98E-04 7.65E-09 5.96E-05 
6 rs183927068 MAP2 2:210288479 0.98 AFR MAP/CS -0.60 1.09 11.29 2.02 8.36E-08 2.05E-09 0.001619 
7 rs75875736 STAC 3:36341106 0.02 AFR PP/ES -3.49 0.58 3.15 0.94 1.23E-03 1.41E-08 0.000108 
8 rs116199364 CLSTN2 3:139951198 0.02 AFR PP/CS 1.94 0.92 -10.54 1.88 2.23E-08 1.04E-07 0.000675 
9 rs114619985 BOD1L 4:13599930 0.02 AFR PP/ES -2.74 0.78 -1.86 1.13 0.04 2.71E-10 2.61E-06 
10 rs201223145 PRDM5 4:121706475 0.97 AFR PP/CS 2.67 0.68 2.91 1.39 0.12 5.91E-09 0.001905 
11 rs147998309 PCDH10 4:133596832 0.99 AFR PP/CS 1.61 1.18 12.94 2.64 1.78E-06 2.41E-09 1.74E-05 
12 rs146622638 GPM6A 4:176524533 0.97 AFR PP/ES 2.76 0.65 0.16 0.98 0.95 4.55E-08 0.000334 
13 rs72723039 IRX2 5:2664169 0.98 AFR PP/CS -1.69 1.10 10.76 1.88 2.39E-08 6.55E-09 0.002064 
14 rs79205226 CDKAL1 6:21103825 0.02 AFR PP/CS 1.46 0.68 -7.94 1.30 1.60E-09 3.38E-09 2.41E-05 
15 rs200495667 ALDH8A1 6:135152480 0.08 ASN PP/CS -2.48 0.41 2.63 0.92 3.11E-03 1.50E-08 0.000378 
16 rs190090939 ACTR3B 7:152802243 0.01 AFR PP/CS -0.01 1.12 -11.94 2.24 1.86E-07 5.41E-09 3.79E-05 
17 rs140994551 CSMD1 8:4449086 0.01 AFR PP/CS 0.43 1.07 -11.39 1.89 4.34E-09 2.07E-11 1.93E-07 
18 rs4841126 LOC157273 8:9144610 0.45 EUR MAP/ES -0.24 0.04 0.10 0.06 0.11 3.59E-09 1.11E-05 
19 rs6601302 LOC157273 8:9239458 0.25 EUR MAP/ES 0.25 0.05 -0.08 0.07 0.32 6.94E-09 2.11E-05 
20 rs7817784 TNKS 8:9682553 0.57 EUR MAP/CS -0.23 0.03 0.05 0.08 0.89 6.93E-13 2.59E-09 
21 rs17151108 MSRA 8:9971119 0.26 EUR MAP/CS 0.20 0.04 0.03 0.09 0.63 1.13E-08 3.26E-05 
22 rs12156238 FAM167A 8:11285135 0.19 EUR MAP/ES -0.30 0.06 0.10 0.08 0.29 1.03E-08 1.69E-05 
23 MERGED_DEL _2_50178   8:79178179 0.01 EUR MAP/CS 1.60 1.34 -9.18 1.86 6.30E-07 1.25E-08 3.56E-05 
24 rs11991823 LRRC69; SLC26A7 8:92188440 0.37 Trans PP/ES -0.23 0.03 0.06 0.05 0.43 1.29E-15 8.89E-11 
25 rs7823377 TRHR 8:110073120 0.59 EUR PP/CS -0.15 0.03 0.02 0.08 0.86 5.80E-06 0.00026 
26 rs76209156 KDM4C 9:7423109 0.99 AFR PP/CS 0.03 1.19 10.43 2.14 1.96E-06 2.94E-08 0.000197 
28 
 
27 rs77548020 FLJ41200; NFIB 9:13480744 0.98 AFR PP/CS 0.75 0.83 7.27 1.59 1.56E-04 1.91E-08 0.00013 
28 rs75872665 LOC100128811 10:25388468 0.99 AFR PP/CS 0.08 1.09 8.94 1.88 3.41E-04 2.80E-08 0.000188 
29 rs76497600 BUB3 10:125119610 0.03 AFR PP/ES -0.79 0.61 -2.65 0.85 0.01 2.29E-08 0.000173 
30 rs148454833 OR52A4 11:5114798 0.98 AFR PP/CS 0.34 0.76 7.09 1.47 8.39E-06 2.16E-08 0.000147 
31 rs186331780 FAM19A2 12:61710810 0.02 AFR PP/CS -2.43 0.89 -4.88 1.66 0.02 3.15E-08 0.007099 
32 rs146924684 AVPR1A 12:63437286 0.99 AFR MAP/ES 4.88 0.83 -3.20 1.22 0.18 5.29E-09 2.62E-05 
33 rs117206641 FBRSL1 12:133086888 0.11 Trans MAP/CS 0.32 0.05 0.03 0.13 0.70 1.14E-10 5.71E-07 
34 rs73212161 TDRD3 13:61261485 0.99 AFR PP/ES -1.39 1.40 7.80 1.77 1.50E-05 1.68E-08 0.006503 
35 rs78265647 IGF1R 15:99247941 0.98 AFR PP/CS -1.71 0.72 7.64 1.28 2.02E-09 8.86E-09 6.09E-05 
36 rs145181522 TOX3 16:52490106 0.02 AFR PP/CS -0.65 0.95 -8.04 1.58 3.67E-05 3.66E-11 3.32E-07 
37 rs114511313 NUDT7 16:77706251 0.98 AFR PP/CS 1.67 0.73 4.06 1.28 0.13 1.63E-08 0.000111 
38 rs75129914 RIT2 18:40267945 0.97 AFR PP/ES 0.32 0.61 3.42 0.85 3.81E-04 2.13E-09 1.80E-05 
39 rs115134409 MALT1; NEDD4L 18:56324467 0.02 AFR PP/CS -0.31 0.77 -6.46 1.29 3.26E-03 3.64E-10 2.92E-06 
40 rs78375085 TNFRSF11A 18:60032891 0.98 AFR PP/ES 4.55 0.77 -5.57 1.21 4.71E-06 1.64E-08 0.000124 
41 rs191056303 PXMP4 20:32306802 0.98 AFR PP/CS 0.15 0.74 7.41 1.47 5.99E-07 1.77E-08 0.000121 
Each locus was determined through LD-based clumping, using ± 1 Mb around index variants, followed by LD threshold of r2 > 0.1. 
Each locus is genome-wide significant (P < 5×10-8) in the combined analyses of Stages 1 and 2 and had FDR q value < 0.05. Positions 
are based on human genome build 37. EA: effect allele; EAF: effect allele frequency; 2 DF Joint P: P-value of the joint test with 2 
degrees of freedom of genetic main and interaction effects. 1 DF Interaction P: P-value of the interaction test with 1 degree of 
freedom; EUR: European ancestry. ALL: trans-ancestry (i.e., combining all ancestry groups through meta-analysis); MAP: mean 
arterial pressure; PP: pulse pressure; CS: current-smoking; ES: ever-smoking. 
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Table 3: Eleven new signals associated with MAP and/or PP that are near known BP loci (but not in LD, r2 < 0.1). 
Locus rsID Nearest Gene Pos Freq1 Race 
Trait/ 
Exposure Effect StdErr 
GxE 
Effect 
GxE 
StdErr 
Interaction  
P Joint P 
FDR q 
value 
1 rs140881076 KAZN 1:15364113 0.01 AFR PP/CS 0.45 1.13 -11.95 1.85 2.30E-03 3.29E-14 4.16E-10 
2 rs2071405 AGT 1:230850658 0.13 Trans MAP/CS 0.28 0.04 -0.18 0.09 0.20 3.02E-12 1.62E-08 
3 rs143802076 C3orf38 3:88646080 0.01 AFR PP/CS -0.50 0.90 -8.54 1.68 8.97E-04 1.33E-09 9.81E-06 
4 rs1009382 TNXB 6:32026107 0.71 EUR PP/CS 0.26 0.04 -0.16 0.08 0.15 4.84E-13 3.30E-09 
5 rs7005363 MSRA 8:10283748 0.54 EUR MAP/ES -0.34 0.04 0.15 0.06 0.02 3.13E-17 1.59E-13 
6 rs187148391 TXN 9:112998518 0.99 HIS MAP/ES 0.09 0.69 4.48 1.03 1.01E-03 1.95E-08 0.013302 
7 rs10894198 ADAMTS8 11:130285493 0.38 Trans PP/CS 0.27 0.03 -0.12 0.07 0.33 1.38E-19 3.19E-15 
8 rs113328593 SNX19 11:130742179 0.02 AFR PP/CS -3.06 0.79 -2.74 1.41 0.10 2.23E-09 1.60E-05 
9 rs1010064 LOC100506393 PDE3A 12:20000315 0.75 Trans MAP/ES 0.24 0.04 -0.12 0.06 0.03 5.91E-11 6.64E-10 
10 rs201977809 LOC338758 12:90095795 0.71 EUR MAP/ES -0.26 0.08 -0.18 0.12 0.22 1.32E-09 4.20E-06 
11 rs201028933 LOC338758 12:90111249 0.79 Trans MAP/ES 0.32 0.08 0.16 0.11 0.28 1.73E-11 9.75E-08 
Each locus was determined through LD-based clumping, using ± 1 Mb around index variants, followed by LD threshold of r2 > 0.1. 
Each locus is genome-wide significant (P < 5×10-8) in the combined analyses of Stages 1 and 2 and had FDR q value < 0.05. Positions 
are based on human genome build 37. EA: effect allele; EAF: effect allele frequency; 2 DF Joint P: P-value of the joint test with 2 
degrees of freedom of genetic main and interaction effects. 1 DF Interaction P: P-value of the interaction test with 1 degree of 
freedom; EUR: European ancestry. ALL: trans-ancestry (i.e., combining all ancestry groups through meta-analysis); MAP: mean 
arterial pressure; PP: pulse pressure; CS: current-smoking; ES: ever-smoking.  
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Figure 1: Study design 
Summary of data included in this study.  
 
Smk: smoking status (considering either current smoking or ever smoking status separately); PC: 
principal component; EUR: European; AFR: African; ASN: Asian; HIS: Hispanic; BRZ: 
Brazilian; TRANS; trans-ancestry (i.e., combining all ancestry groups through meta-analysis) 
 
  
TRANS 
n=480,178 
Genome-wide analyses of genetic variants imputed using the 1000 Genomes Project 
reference panel 
MAP (or PP) ~ SNP + Smk + Smk * SNP + age + sex (+ PC’s) (in all subjects) 
MAP (or PP) ~ SNP + age + sex (+ PC’s) (in each group stratified by smoking status)  
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EUR 
n=80,552 
AFR 
n=27,118 
ASN 
n=13,438 
HSP 
n=8,805 
TRANS 
n=129,913 
1,692 significant (P ≤ 5×10
-8
) and 2,681 suggestive (P ≤ 10
-6
) 
 
EUR 
n=305,513 
AFR 
n=7,786 
ASN 
n=148,932 
HSP 
n=13,533 
BRZ 
n=4,414 
All analyses for 2 traits (MAP, PP) × 2 smoking exposures (current smoker, ever smoker) 
Association analysis of select variants 
MAP (or PP) ~ SNP + Smk + Smk * SNP + age + sex (+ PC’s) (in all subjects)  
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Figure 2: Venn diagram of loci/signals associated with the 4 BP traits 
The diagram shows 133 loci and/or signals that were identified through gene-smoking 
interactions. We had reported 81 loci associated with SBP/DBP,14 among which 37 showed 
association with MAP or PP. In this paper, we newly identified 41 loci (Table 2) and 11 signals 
near known BP loci (Table 3) that are unique to MAP and/or PP (to a total of 52 new 
loci/signals).  
SBP: systolic blood pressure; DBP, diastolic blood pressure; MAP: mean arterial pressure; PP: 
pulse pressure 
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Figure 3: Smoking-specific genetic effect sizes for MAP or PP  
Among the 139 loci significantly associated with MAP and/or PP, 8 loci show significant 
interactions with smoking exposure status in African ancestry (1 DF interaction P < 5×10-8). 
Smoking-specific effect estimates and 95% confidence intervals for variants associated with BP 
traits are shown as red and blue squares for current-smokers and non-current smokers, 
respectively.  
 
MAP: mean arterial pressure; PP: pulse pressure; CS: current-smoking 
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Figure 4: Smoking-specific estimates of variance explained in European ancestry 
The variants with P ≤ 5×10-8 explained 1.9% of variance in MAP and 0.5% of variance in PP, 
whereas variants with P ≤ 10-4 explained 16% of variance in MAP and 11% of variance in PP. 
The vertical line corresponds to FDR = 0.1. 
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Figure 5: LocusZoom plots for 4 selected loci associated with MAP and/or PP  
(A) rs140881076 (chr1:15364113) was identified in an analysis of individuals of African 
ancestry and is intronic to KAZN; neighboring genes have been implicated in cardiovascular 
traits. FHAD1 is a long non-coding RNA overexpressed in heart failure, TMEM51 has been 
associated with contractile function in cardiomyocytes, and CASP9 plays a central role in 
cardiomyocyte apoptosis. 
 (B) rs140994551 (chr8:4449086), intronic to CSMD1, shows interaction with current smoking in 
individuals of African Ancestry. CSMD1 are shown to be associated with insulin resistance and 
BP in the spontaneously hypertensive rats. CSMD1 is also suggestively-associated with studies 
of addiction and related disorders.   
(C) rs11991823 (chr8:92188440) was associated with PP in trans-ancestry analyses and in 
intronic to LRRC69. The nearby gene SLC26A7 encodes a chloride/bicarbonate-exchanger 
expressed specifically in the renal outer medullary collecting duct. 
(D) rs146924684 (chr12:63437286) was association with MAP in individuals of African 
ancestry. The nearby gene AVPR1A is widely expressed including in vascular smooth muscle 
cells, kidney, myocardium, and brain.  
CurSmk: current smoking status; EverSmk: ever smoking status; MAP: mean arterial pressure; 
PP: pulse pressure 
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